Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Molecular Docking Analysis of Steroid-based Copper Transporter 1 Inhibitors

ONAT KADIOGLU, JULIANNA SERLY, EAN-JEONG SEO, IRÉN VINCZE, CSABA SOMLAI, MOHAMED E.M. SAEED, JÓZSEF MOLNÁR and THOMAS EFFERTH
Anticancer Research December 2015, 35 (12) 6505-6508;
ONAT KADIOGLU
1Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JULIANNA SERLY
2Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EAN-JEONG SEO
1Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
IRÉN VINCZE
3Department of Organic Chemistry, University of Szeged, Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CSABA SOMLAI
4Department of Medical Chemistry, University of Szeged, Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MOHAMED E.M. SAEED
1Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JÓZSEF MOLNÁR
2Department of Medical Microbiology and Immunobiology, Faculty of Medicine, University of Szeged, Szeged, Hungary
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: molnar.jozsef@med.u-szeged.hu efferth@uni-mainz.de
THOMAS EFFERTH
1Department of Pharmaceutical Biology, Johannes Gutenberg University, Mainz, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: molnar.jozsef@med.u-szeged.hu efferth@uni-mainz.de
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Copper transporter 1 (CTR1) represents an important determinant of cisplatin resistance. A series of 35 semi-substituted steroids were recently investigated on cisplatin-resistant CTR1-expressing A2780cis ovarian carcinoma cells as well as their parental sensitive counterparts regarding their cytotoxic and resistance-reversing features. In the present investigation, three compounds (4, 5, 25) were selected for molecular docking analysis on the homology-modelled human CTR1 transmembrane domain. Steroids 4, 5 and 25 interacted with CTR1 at a similar docking pose and with even higher binding affinities than the known CTR1 inhibitor, cimetidine. Applying the defined docking mode, the binding energies were found to be −7.15±<0.001 kcal/mol (compound 4), −8.71±0.06 kcal/mol (compound 5), −7.63±0.01 kcal/mol (compound 25), and −5.05±0.02 kcal/mol (for cimetidine). These steroids have the potential for further development as CTR1 inhibitors overcoming cisplatin resistance.

  • Cancer
  • drug resistance
  • copper transporter
  • molecular docking

Abbreviations: ABC, ATP-binding cassette; CTR 1/2, copper transporter 1/2; MDR, multidrug resistance.

Cancer mortality accounts for approximately one eighth of all deaths worldwide. The annual cancer incidence doubled during the past 30 years (1). Around 1.5 million new cases and 0.6 million deaths are projected in the United States for 2015 (2). Carcinogenesis underlies complex mechanisms and single-target approaches are inadequate to fight cancer. Drug resistance caused by ATP-binding cassette (ABC) or copper transporters (3-5) hamper successful cancer chemotherapy (6). ABC-transporters cause multi-drug resistance (MDR) (7-9). Cisplatin resistance is another type mediated by copper transporters (CTRs or SLC31) and P-type transporters, that are localized in the plasma membrane (e.g. CTR1) or intracellular membranes of late endosomes and lysosomes (CTR2 or P-type copper transporters α and β (ATP7A/B)) (10, 11).

Copper is essential for growth and development. However, its cellular accumulation beyond homeostatic limits is toxic (12). CTR1 is the main copper uptake transporter. It consists of 190 amino acids with three transmembrane domains, whose gene is localized on chromosome 9. CTR1 forms oligomeric (mostly homo-trimer) complexes facilitating pore formation for copper uptake (13, 14). The methionine- and histidine-rich amino terminus is important for copper binding (15). CTR1 represents an ubiquitously expressed high-affinity importer of reduced copper (Cu+), which regulates the sensitivity to platinum-containing drugs. The associations between CTR1, immune function, and disorders such as Alzheimer's disease or cancer make this protein an attractive target for therapeutic interventions (16). CTR1 confers cancer drug resistance (11, 17, 18). Decreased platin accumulation is related to up-regulated CTR1 in ovarian, testicle, lung, head and neck carcinoma (11).

The CTR2 gene is localized on chromosome 9 and encodes a 143-amino-acid protein. CTR2 functions as homo-multimer similar to CTR1. Low CTR2 levels increased the cellular uptake and cytotoxicity of cisplatin and carboplatin (19, 20).

Several studies have demonstrated that down-regulation of CTR1 reduced uptake and sensitivity, whereas down-regulation of CTR2 enhanced both (21-24). Cisplatin degraded CTR1 in ovarian cancer cells, whereas it increased CTR2 expression. Copper depletion caused CTR2 disappearance, whereas excessive copper increased it. CTR1 and CTR2 revealed opposite effects (25). CTR1 inhibitors open new strategies in reversing platinum resistance (15).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Structures of steroids 4, 5 and 25.

Herein, we generated a homology-based three-dimensional CTR1 model and performed in silico molecular docking studies to predict docking poses (binding position) and binding energies of the selected steroid compounds that we previously reported to inhibit CTR1 and overcome CTR1-mediated cisplatin resistance (26).

Materials and Methods

Compounds. Semi-substituted steroids and their derivatives in complexes with platinum and copper (I). Previously, we synthesized and investigated 35 modified steroid derivatives (1-35) regarding their CTR1 inhibition and modulation of cisplatin resistance (26-31). The best three compounds (4, 5, 25) were selected for the present investigation (Figure 1).

Molecular docking. Transmembrane domains of human CTR1 were compiled as single-structure models by homology modelling (32). PubChem was referred for the 3-D structure of the control drug, cimetidine (https://pubchem.ncbi.nlm.nih.gov/). Blind and defined molecular docking calculations were performed with AutoDock4, as previously described (33, 34).

Initial blind dockings were performed with cimetidine and compounds 4, 5 and 25. Blind docking calculations were performed by covering the whole protein. The number of energy evaluations was set to 25,000,000 and number of runs 250. Defined docking calculations were performed by covering the residues involved in hydrogen bonds or hydrophobic interactions with each ligand by blind docking. Docking parameters of defined dockings were set to 250 runs and 2,500,000 energy evaluations. Lamarckian Genetic Algorithm was chosen for docking calculations. For visualization, AutodockTools-1.5.7rc1 was used. The surface representation image showing the binding pocket of transmembrane domains of human CTR1 was created with Visual Molecular Dynamics (VMD) software developed by the Theoretical and Computational Biophysics group at the Beckman Institute, University of Illinois at Urbana-Champaign (http://www.ks.uiuc.edu/Research/vmd/).

Results and Discussion

In order to investigate the binding of steroids 4, 5 and 25 to transmembrane domains of human CTR1, we performed in silico molecular docking. We compiled CTR1 transmembrane domains to a single structure by homology modeling. Since cimetidine reduced cisplatin uptake, we chose it as a control drug (35, 36). All three steroids bound to the same pharmacophore as cimetidine with high binding affinities (i.e. low kcal/mol values) in both blind and defined docking approaches (Figure 2 and Tables I and II). Binding affinity was considered high at binding energies around −8 kcal/mol (37).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Molecular docking studies on the homology-modelled CTR1 transmembrane domain (surface and ribbon representation). Docking poses of compound 4, 5, 25 and control drug cimetidine are depicted.

Cimetidine revealed low binding affinities (blind docking: −4.65±0.03 kcal/mol, defined docking: −5.03±0.02 kcal/mol). However, compound 4 (blind docking: −7.10±0.00 kcal/mol, defined docking: −7.15±<0.001 kcal/mol), compound 5 (blind docking: −8.78±0.06 kcal/mol, defined docking: −8.71±0.06 kcal/mol) and compound 25 (blind docking: −7.63±0.01 kcal/mol, defined docking: −7.62±0.01 kcal/mol) bound to CTR1 with even higher affinities than cimetidine (Tables I and II). Cimetidine did not form hydrogen bonds with CTR1, whereas compound 4 did (blind docking: Phe74 and Trp177, defined docking: Trp177). This was also observed for compound 5 (defined docking: Trp177) and compound 25 (blind docking: Val75, defined docking: Val75) (Tables I and II).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

In silico blind molecular docking to transmembrane domains of human copper transporter 1 (CTR1). Dockings were performed three times with 250 numbers of runs by covering the whole protein.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

In silico defined molecular docking to transmembrane domains of human CTR1. Dockings were performed three times with 250 numbers of runs by covering the residues found by blind docking.

In the present study, three selected semi-substituted steroids (4, 5, 25) previously described by our group (26) were subjected to in silico molecular docking studies. They interacted with CTR1 transmembrane domain with stronger affinity than the known inhibitor, cimetidine (35). The potential of these compounds is highlighted by the fact that the predicted binding energies were even higher than those for cimetidine. Further pre-clinical and clinical studies are warranted to clarify the therapeutic potential of compounds 4, 5 and 25.

On the other hand, the toxicity of platinum compounds has to be also taken into account. Ototoxicity, nephrotoxicity, and hepatotoxicity are serious side-effects of cisplatin therapy, which may be managed by natural compounds (36, 38, 39). Therefore, CTR1 inhibitors such as natural or synthetic ones, as the ones introduced by our group, have to be carefully investigated to ensure their safety.

Footnotes

  • Conflicts of Interest

    The Authors declare that there exist no conflicts of interest.

  • Received August 5, 2015.
  • Revision received October 9, 2015.
  • Accepted October 16, 2015.
  • Copyright© 2015 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Boyle P,
    2. Levin B
    : International Agency for Research on Cancer. World Health Organization. World cancer report 2008. International Agency for Research on Cancer. WHO Press, Lyon Geneva, 2008.
  2. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Jemal A
    : Cancer statistics, 2015. CA: Cancer J Clinicians 65: 5-29, 2015.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Ayrton A,
    2. Morgan P
    : Role of transport proteins in drug discovery and development: a pharmaceutical perspective. Xenobiotica 38: 676-708, 2008.
    OpenUrlPubMed
    1. Efferth T
    : The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr Mol Med 1: 45-65, 2001.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Howell SB,
    2. Safaei R,
    3. Larson CA,
    4. Sailor MJ
    : Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77: 887-894, 2010.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Serly J
    : Inhibition of drug resistance in two cancer cell lines (MDR And A2780cis) in vitro and the role of selected single nucleotide polymorphisms in cancer. Ph.D. Thesis. University of Szeged, Szeged, Hungary, 2012.
  6. ↵
    1. Szabó D,
    2. Keyzer H,
    3. Kaiser HE,
    4. Molnár J
    : Reversal of multidrug resistance of tumor cells. Anticancer Res 20: 4261-4274, 2000.
    OpenUrlPubMed
    1. Gillet JP,
    2. Efferth T,
    3. Remacle J
    : Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237-262, 2007.
    OpenUrlPubMed
  7. ↵
    1. Saeed M,
    2. Khalid H,
    3. Sugimoto Y,
    4. Efferth T
    : The lignan, (−)-sesamin reveals cytotoxicity toward cancer cells: pharmaco-genomic determination of genes associated with sensitivity or resistance. Phytomedicine 21: 689-696, 2014.
    OpenUrlPubMed
  8. ↵
    1. Konkimalla VB,
    2. Kaina B,
    3. Efferth T
    : Role of transporter genes in cisplatin resistance. In Vivo 22: 279-283, 2008.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Kuo MT,
    2. Fu S,
    3. Savaraj N,
    4. Chen HH
    : Role of the human high-affinity copper transporter in copper homeostasis regulation and cisplatin sensitivity in cancer chemotherapy. Cancer Res 72: 4616-4621, 2012.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Ohrvik H,
    2. Thiele DJ
    : The role of Ctr1 and Ctr2 in mammalian copper homeostasis and platinum-based chemotherapy. J Trace Elements Med Biol 31: 178-182, 2015.
    OpenUrlPubMed
  11. ↵
    1. Veldhuis NA,
    2. Gaeth AP,
    3. Pearson RB,
    4. Gabriel K,
    5. Camakaris J
    : The multi-layered regulation of copper translocating P-type ATPases. Biometals 22: 177-190, 2009.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Eisses JF,
    2. Kaplan JH
    : Molecular characterization of hCTR1, the human copper uptake protein. J Biol Chem 277: 29162-29171, 2002.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Safaei R,
    2. Howell SB
    : Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hemat 53: 13-23, 2005.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Schweigel-Rontgen M
    : The families of zinc (SLC30 and SLC39) and copper (SLC31) transporters. Curr Top Membr 73: 321-355, 2014.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Holzer AK,
    2. Samimi G,
    3. Katano K,
    4. Naerdemann W,
    5. Lin X,
    6. Safaei R,
    7. Howell SB
    : The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells. Mol Pharmacol 66: 817-823, 2004.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Howell SB,
    2. Safaei R,
    3. Larson CA,
    4. Sailor MJ
    : Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol 77: 887-894, 2010.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Blair BG,
    2. Larson CA,
    3. Safaei R,
    4. Howell SB
    : Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res 15: 4312-4321, 2009.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Blair BG,
    2. Larson CA,
    3. Adams PL,
    4. Abada PB,
    5. Pesce CE,
    6. Safaei R,
    7. Howell SB
    : Copper transporter 2 regulates endocytosis and controls tumor growth and sensitivity to cisplatin in vivo. Mol Pharmacol 79: 157-166, 2011.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Samimi G,
    2. Safaei R,
    3. Katano K,
    4. Holzer AK,
    5. Rochdi M,
    6. Tomioka M,
    7. Goodman M,
    8. Howell SB
    : Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clin Cancer Res 10: 4661-4669, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Rabik CA,
    2. Maryon EB,
    3. Kasza K,
    4. Shafer JT,
    5. Bartnik CM,
    6. Dolan ME
    : Role of copper transporters in resistance to platinating agents. Cancer Chemother Pharmacol 64: 133-142, 2009.
    OpenUrlCrossRefPubMed
    1. Abada P,
    2. Howell SB
    : Regulation of cisplatin cytotoxicity by cu influx transporters. Metal-Based Drugs 2010: 317581, 2010.
    OpenUrl
  20. ↵
    1. Kalayda GV1,
    2. Wagner CH,
    3. Jaehde U
    : Relevance of copper transporter 1 for cisplatin resistance in human ovarian carcinoma cells. J Inorg Biochem 116: 1-10, 2012.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Blair BG,
    2. Larson CA,
    3. Adams PL,
    4. Abada PB,
    5. Safaei R,
    6. Howell SB
    : Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol 77: 912-921, 2010.
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Serly J,
    2. Vincze I,
    3. Somlai C,
    4. Hodoniczki L,
    5. Molnar J
    : Synthesis and comparison of the antitumor activities of steroids on ABCB1-transfected mouse lymphoma and human ovary carcinoma. Lett Drug Dis Discover 8: 138-147, 2011.
    OpenUrl
    1. Vincze I,
    2. Somlai C,
    3. Schneider G,
    4. Dombi G,
    5. Kálmán A
    (1987) 2-(Hydroxymethyl)androstene derivatives. Liebigs Ann Chem 6: 499-504, 1987.
    OpenUrl
    1. Weisz-Vincze IK,
    2. Deák Á
    : The base-catalysed reaction of androst-5-en-3β-ol-17-one with formaldehyde. Eur J Steroids 2: 139-156, 1967.
    OpenUrl
    1. Vincze I,
    2. Somlai C,
    3. Schneider G,
    4. Dombi G,
    5. Mak M
    (eds): Steroids. 45. Neighboring group participation. 12. Decomposition of (Z)-16-amidomethylene-17-beta-hydroxysteroids mediated by neighboring group participation. Liebigs Ann Chem, 3: 1992.
    1. Vincze I,
    2. Lokos M,
    3. Bakos T,
    4. Dancsi A,
    5. Mak M
    : Steroids. 49. Investigations on the dehydration of 17 alpha-ethynyl-17 beta-hydroxysteroids. Steroids 58: 220-224, 1993.
    OpenUrlPubMed
  23. ↵
    1. Szendi Z,
    2. Dombi G,
    3. Vincze I
    : Steroids. 53. New routes to aminosteroids. Monatshefte Chemie 127: 1189-1196, 1996.
    OpenUrl
  24. ↵
    1. Sutcliffe MJ,
    2. Smeeton AH,
    3. Wo ZG,
    4. Oswald RE
    : Three-dimensional models of glutamate receptors. Faraday Discussions 111: 259-272, 1998. Discussion 331-243.
    OpenUrlPubMed
  25. ↵
    1. Morris GM,
    2. Huey R,
    3. Lindstrom W,
    4. Sanner MF,
    5. Belew RK,
    6. Goodsell DS,
    7. Olson AJ
    : AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791, 2009.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Zeino M,
    2. Saeed ME,
    3. Kadioglu O,
    4. Efferth T
    : The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein - a well-known, yet poorly understood drug transporter. Invest New Drugs 32: 618-625, 2014.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Pabla N,
    2. Murphy RF,
    3. Liu K,
    4. Dong Z
    : The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am J Physiol Renal Physiol 296: F505-F511, 2009.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Ding D,
    2. He J,
    3. Allman BL,
    4. Yu D,
    5. Jiang H,
    6. Seigel GM,
    7. Salvi RJ
    : Cisplatin ototoxicity in rat cochlear organotypic cultures. Hearing Res 282: 196-203, 2011.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Chushak Y,
    2. Stone MO
    : In silico selection of RNA aptamers. Nucleic Acids Res 37: e87, 2009.
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Sahu BD,
    2. Kuncha M,
    3. Sindhura GJ,
    4. Sistla R
    : Hesperidin attenuates cisplatin-induced acute renal injury by decreasing oxidative stress, inflammation and DNA damage. Phytomedicine 20: 453-460, 2013.
    OpenUrlPubMed
  31. ↵
    1. Jin J,
    2. Li M,
    3. Zhao Z,
    4. Sun X,
    5. Li J,
    6. Wang W,
    7. Huang M,
    8. Huang Z
    : Protective effect of Wuzhi tablet (Schisandra sphenanthera extract) against cisplatin-induced nephrotoxicity via Nrf2-mediated defense response. Phytomedicine 22: 528-535, 2015.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 35 (12)
Anticancer Research
Vol. 35, Issue 12
December 2015
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Molecular Docking Analysis of Steroid-based Copper Transporter 1 Inhibitors
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
10 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Molecular Docking Analysis of Steroid-based Copper Transporter 1 Inhibitors
ONAT KADIOGLU, JULIANNA SERLY, EAN-JEONG SEO, IRÉN VINCZE, CSABA SOMLAI, MOHAMED E.M. SAEED, JÓZSEF MOLNÁR, THOMAS EFFERTH
Anticancer Research Dec 2015, 35 (12) 6505-6508;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Molecular Docking Analysis of Steroid-based Copper Transporter 1 Inhibitors
ONAT KADIOGLU, JULIANNA SERLY, EAN-JEONG SEO, IRÉN VINCZE, CSABA SOMLAI, MOHAMED E.M. SAEED, JÓZSEF MOLNÁR, THOMAS EFFERTH
Anticancer Research Dec 2015, 35 (12) 6505-6508;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results and Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Comprehensive Analysis of KREMEN2 as an Immunotherapeutic and Prognostic Biomarker in Pan-Cancer
  • PD-L1 mRNA Detection in Immunohistochemically Negative Patients: A Complementary Method for a Better Treatment Selection?
  • Immune Cell Infiltration and Clinical Significance of Angiogenesis-related Genes in Lung Adenocarcinoma
Show more Experimental Studies

Similar Articles

Keywords

  • cancer
  • drug resistance
  • copper transporter
  • molecular docking
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire